Statistics at a Glance
At a Glance
Estimated New Cases in 2019 42,030
% of All New Cancer Cases 2.4%
Estimated Deaths in 2019 31,780
% of All Cancer Deaths 5.2%
|Year||New Cases - SEER 9||New Cases - SEER 13||Deaths - U.S.||Percent Surviving 5 Years - SEER 9|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
Number of New Cases and Deaths per 100,000: The number of new cases of liver and intrahepatic bile duct cancer was 8.8 per 100,000 men and women per year. The number of deaths was 6.5 per 100,000 men and women per year. These rates are age-adjusted and based on 2012-2016 cases and deaths.
Lifetime Risk of Developing Cancer: Approximately 1.0 percent of men and women will be diagnosed with liver and intrahepatic bile duct cancer at some point during their lifetime, based on 2014-2016 data.
Prevalence of This Cancer: In 2016, there were an estimated 83,081 people living with liver and intrahepatic bile duct cancer in the United States.
How Many People Survive 5 Years Or More after Being Diagnosed with Liver and Intrahepatic Bile Duct Cancer?
Relative survival statistics compare the survival of patients diagnosed with cancer with the survival of people in the general population who are the same age, race, and sex and who have not been diagnosed with cancer. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 18 2009-2015. Gray figures represent those who have died from liver and intrahepatic bile duct cancer. Green figures represent those who have survived 5 years or more.
Survival by Stage
Cancer stage at diagnosis, which refers to extent of a cancer in the body, determines treatment options and has a strong influence on the length of survival. In general, if the cancer is found only in the part of the body where it started it is localized (sometimes referred to as stage 1). If it has spread to a different part of the body, the stage is regional or distant. The earlier liver and intrahepatic bile duct cancer is caught, the better chance a person has of surviving five years after being diagnosed. For liver and intrahepatic bile duct cancer, 44.1% are diagnosed at the local stage. The 5-year survival for localized liver and intrahepatic bile duct cancer is 32.6%.
|Stage||Percent of Cases||5-Year Relative Survival|
Confined to Primary Site
Spread to Regional Lymph Nodes
Cancer Has Metastasized
SEER 18 2009-2015, All Races, Both Sexes by SEER Summary Stage 2000
Number of New Cases and Deaths
How Common Is This Cancer?
Compared to other cancers, liver and intrahepatic bile duct cancer is relatively rare.
|Rank||Common Types of Cancer||Estimated New
|1.||Breast Cancer (Female)||268,600||41,760|
|2.||Lung and Bronchus Cancer||228,150||142,670|
|5.||Melanoma of the Skin||96,480||7,230|
|8.||Kidney and Renal Pelvis Cancer||73,820||14,770|
|13.||Liver and Intrahepatic Bile Duct Cancer||42,030||31,780|
Liver and intrahepatic bile duct cancer represents 2.4% of all new cancer cases in the U.S.
In 2019, it is estimated that there will be 42,030 new cases of liver and intrahepatic bile duct cancer and an estimated 31,780 people will die of this disease.
Who Gets This Cancer?
Liver cancer is more common in men than women, and among Asian/Pacific Islander and American Indian/Alaska Native populations. The number of new cases of liver and intrahepatic bile duct cancer was 8.8 per 100,000 men and women per year based on 2012-2016 cases.
|American Indian/Alaska Native||19.3|
|American Indian/Alaska Native||8.5|
SEER 21 2012-2016, Age-Adjusted
|Age Range||Percent of New Cases|
Liver and intrahepatic bile duct cancer is most frequently diagnosed among people aged 55-64.
SEER 21 2012-2016, All Races, Both Sexes
Who Dies From This Cancer?
Liver and intrahepatic bile duct cancer is the fifth leading cause of cancer death in the United States. The number of deaths was 6.5 per 100,000 men and women per year based on 2012-2016 deaths.
|American Indian/Alaska Native||14.4|
|American Indian/Alaska Native||7.4|
U.S. 2012-2016, Age-Adjusted
|Age Range||Percent of Deaths|
The percent of liver and intrahepatic bile duct cancer deaths is highest among people aged 55-64.
U.S. 2012-2016, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of the number of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, rates for new liver and intrahepatic bile duct cancer cases have been rising on average 2.1% each year over the last 10 years. Death rates have been rising on average 2.4% each year over 2007-2016. 5-year survival trends are shown below.
More About This Cancer
Cancer and the Liver
Figure: Anatomy of the liver; drawing shows the right and left front lobes of the liver, bile ducts, gallbladder, stomach, spleen, pancreas, colon, and small intestine. The two back lobes of the liver are not shown.
The liver is one of the largest organs in the body. It has four lobes and fills the upper right side of the abdomen inside the rib cage. The liver has many important functions, including:
- Filtering harmful substances from the blood so they can be passed from the body in stools and urine.
- Making bile to help digest fats from food.
- Storing glycogen (sugar), which the body uses for energy.
This summary refers to primary liver cancer (cancer that begins in the liver). Treatment of metastatic liver cancer, which is cancer that begins in other parts of the body and spreads to the liver, is not included in these statistics.
Here are some resources for learning more about liver cancer.
- More about risk factors for liver cancer
- More about symptoms and diagnosis of liver cancer
- More about treatment options for liver cancer
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within:
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/livibd.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse the SEER Cancer Statistics Review. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in the SEER Cancer Statistics Review. In some cases, different year spans may be used. Estimates for the current year are based on past data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.